These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 94841)
1. [Medical treatment of prostatic adenoma]. Schulman CC; Chantrie M; Giannakopoulos X; De Sloover CR Brux Med; 1979 Oct; 59(10):467-70. PubMed ID: 94841 [No Abstract] [Full Text] [Related]
2. [Treatment of prostatic adenoma with medroxyprogesterone acetate]. Maltoni G; Zoli M Minerva Urol; 1972; 24(5):184-99. PubMed ID: 4141051 [No Abstract] [Full Text] [Related]
3. [Experience with medroxyprogesterone acetate in adenoma of the prostate]. Sesia G; Ferrando U; Laudi M; Fontana G Minerva Urol; 1970; 22(3):81-8. PubMed ID: 4099513 [No Abstract] [Full Text] [Related]
4. [Hormonal treatment of prostatic hypertrophy with special reference to the usefulness of gestagens]. Musierowicz A Wiad Lek; 1974 Nov; 27(22):1985-8. PubMed ID: 4140619 [No Abstract] [Full Text] [Related]
5. [Medroxyprogesterone acetate in urinary retention caused by inoperable prostatic hypertrophy]. Menozzi D; Debbia F Minerva Urol; 1970; 22(3):89-105. PubMed ID: 4099514 [No Abstract] [Full Text] [Related]
7. [Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC]. Pavone-Macaluso M; Martínez-Piñeiro JA; de Voogt H; Lardennois B; Nasta A; Zolfanelli R; Barasolo E; De Pauw M; Suciu S; Sulvester R Arch Esp Urol; 1982; 35(5):304-11. PubMed ID: 6217788 [No Abstract] [Full Text] [Related]
9. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761. Pavone-Macaluso M; Ingargiola GB; de Voogt H; Viggiano G; Barasolo E; Lardennois B; De Pauw M; Sylvester R Prog Clin Biol Res; 1987; 243A():379-82. PubMed ID: 2958862 [No Abstract] [Full Text] [Related]
10. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study. Tveter KJ; Hagen S; Holme I; Klepp O; Kloster SE; Muri O; Poulsen C; Sander S; Sivertsen S; Urnes T Scand J Urol Nephrol; 1990; 24(4):243-7. PubMed ID: 2148830 [TBL] [Abstract][Full Text] [Related]
11. Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma. Tomic R; Ljungberg B; Damber JE Scand J Urol Nephrol Suppl; 1988; 110():185-7. PubMed ID: 2973122 [No Abstract] [Full Text] [Related]
12. [Raveron treatment of prostatic adenoma in the light of uroflowmetry (on the basis of 20 cases)]. Janosz F; Zieliński J Pol Przegl Chir; 1975 Nov; 47(11A):1441-4. PubMed ID: 54910 [No Abstract] [Full Text] [Related]
13. [Treatment of prostatic hypertrophy with synthetic progestational hormones]. Apicella F; Romanelli B Minerva Urol; 1971; 23(5):220-4. PubMed ID: 4110157 [TBL] [Abstract][Full Text] [Related]
14. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group. Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735 [No Abstract] [Full Text] [Related]
15. [Functional state of the adrenal cortex in cancer and adenoma of the prostate in the process of estrogen therapy]. Klepikov FA; Genes SG; Popova SS Urol Nefrol (Mosk); 1972; 37(6):38-42. PubMed ID: 4124660 [No Abstract] [Full Text] [Related]
17. High-dose medroxyprogesterone acetate in patients with renal adenocarcinoma and measurable lung metastases: a phase II study. Kjaer M; Frederiksen PL Cancer Treat Rep; 1986 Mar; 70(3):431-2. PubMed ID: 2937534 [No Abstract] [Full Text] [Related]
18. [Medroxyprogesterone acetate. Contributive treatment in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency in children]. La Selve H; Sempé M; Morel Y; Forest MG; de Peretti E; David M Arch Fr Pediatr; 1985; 42(7):511-6. PubMed ID: 2935112 [TBL] [Abstract][Full Text] [Related]